Key Milestones

2011-10

– Received accreditation for compliance with European Good Manufacturing Practices standards.
-18 regulatory filings including 8 USDMF, 1 Canadian DMF and 9 Certificate of Suitability with EDQM.
-Received ‘Certificate of Suitability’ (COS) for one of its key molecules- Cefixime in the European Union (EU)
-Received DNV’s certificate for OHSAS 18001-2007 standards.
-Successfully cleared over 20 audits from Multinational Companies across the Globe.
-Commencements of commercial operations in the Multipurpose block 2 at Derabassi that added 325 TPA Cephalosporin capacities
-Recognized as a Star Export house by the Ministry of Commerce
-Filed 7 patents applications in FY 11 related to non-infringing and improved processes in the non-antibiotics pace.

-Received WHO Good Manufacturing Practices certificate for Derabassi facility

2009-10

– Received WHO Good Manufacturing Practices certificate for Derabassi facility
– Accredited by ISO-14001-2004 for Environmental Management
– Commissioned new Custom Synthesis and R&D Centre at HSIIDC , Barwala,Haryana
– Draft Red Herring Prospectus filed for the company’s Initial Public Offer
– Adapted a customized ERP system for enhancing productivity
– Filed six DMFs in the US and EU
– Addition of 6 new Cephalosporin APIs in the product basket

2008-09

– Diversified into Custom Synthesis for Innovator Companies

– Expanded the product basket with Sterile Cephalosporin API capacities

– Commissioned two plants for additional Cephalosporin APIs

– Eight DMFs filed

– Registered presence in 39 countries

2007-08

– Diversified into Cephalosporins

– Filed three DMFs in US

– Established a Sterile Facility

– R&D Wing commissioned

2005-06

– Filed COS for two Penicillin APIs in the EU

2003-05

– Commenced Commercial Operations of PDL II at Panchkula

2000-02

– Commenced Contract Manufacturing for DSM and Ranbaxy.

1997-98

– Commenced Commercial Operations of PDL-I at Derabassi for Penicillin API and API Intermediates